Special Events

 

Shira Doron is currently the Hospital Epidemiologist as well as Director of the Antimicrobial Stewardship Program at Tufts Medical Center and Associate Professor of Medicine at Tufts University School of Medicine. Dr. Doron is board certified in infectious diseases.
 
Dr. Doron is a graduate of the George Washington University School of Medicine and Health Sciences. She completed an internship in internal medicine at the University of California, San Diego, and residency at the George Washington University Hospital. She completed her fellowship training in Infectious Diseases at Tufts Medical Center, along with a Master’s Degree in Clinical Research at the Sackler School of Graduate Biomedical Sciences at Tufts University. Her research interests include antimicrobial resistance, antimicrobial stewardship, and hospital acquired infections.
 
Dr. Doron is known locally and nationally for her expertise in antimicrobial stewardship and infection control. She has held contracts with the Massachusetts Department of Public Health, funded by the Centers for Disease Control and Prevention, to support healthcare facilities throughout the region in their efforts to improve their stewardship and infection control initiatives. She is vice chair of the Infectious Diseases Society of America’s Centers of Excellence subcommittee and chair of the Infectious Diseases Society of America’s Centers of Excellence review committee.

 

 

 

Julie Rubinstein is the President of Adaptive Biotechnologies. Ms. Rubinstein joined Adaptive in 2011 as the head of Corporate and Business Development. In 2016, she became the Chief Business Officer and led the company’s Life Sciences Research Business through two years of double-digit growth. Then, in February 2018, she began serving as President, overseeing the expansion of all of the business lines including Life Sciences Research, Clinical Diagnostics, and Drug Discovery, with continued oversight of Corporate and Business Development functions. Prior to joining Adaptive, Ms. Rubinstein held various worldwide commercial development roles at Pfizer Oncology, primarily focusing on cancer immunotherapy. She also held multiple positions at Johnson & Johnson’s Ethicon Endo-Surgery division, where she helped commercialize a breast cancer diagnostic device in major European markets. She began her career in Morgan Stanley’s Global Health Care Group as a financial analyst. Ms. Rubinstein holds a dual degree, summa cum laude and Phi Beta Kappa, from the University of Pennsylvania’s Undergraduate Wharton School and Annenberg School of Communications, with a minor in French. She also holds an MBA from Harvard Business School. She currently serves on the Board of Trustees for The Valerie Fund, a pediatric oncology organization in New Jersey and New York.